Bergamo Lymphoid Cancer Registry

A.O. Ospedale Papa Giovanni XXIII6,000 enrolled

Overview

This registry has been established to gain a better understanding of the clinical and biological characteristics and outcome of patients with lymphoid cancer

Lymphoid cancer including Hodgkin disease, non-Hodgkin lymphomas (NHL) and myeloma, represents the most common hematologic malignancy. Despite the overall prognosis improved in the last 10 years, there are many open issues that need to be addressed, specifically refractoriness to standard treatment, disease recurrence and outcome with new drug in the so called "real world" setting. Since the Hematology and Bone Marrow Transplant Unit at "Ospedale Papa Giovanni XIII" of Bergamo has developed specific tools to collect clinical data thought fully validated electronic charts and biological specimens thanks to a regulatory compliant biobanking program, the aim of this study is to collect clinical and biological information of lymphoid cancer patients. The cohort of patients enrolled will permit to analyze the practice pattern, perform biological correlative studies of great translational potential with relevance to clinical practice.

Study Type

OBSERVATIONAL

Enrollment

6,000

Conditions

Hodgkin Lymphoma Non Hodgkin Lymphoma Myeloma

Interventions

Patient registryOTHER

Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female patients 18 years or older * Written informed consent * Confirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma Exclusion Criteria: \- Unconfirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma

Locations (1)

Hematology and Bone Marrow Transplant Unit, A.O. Ospedale Papa Giovanni XXIII

Bergamo, Italy

RECRUITING

Outcomes

Primary Outcomes

Overall survival

Analyzed for all patients as time from diagnosis to death as a result of any cause, stratified according to intervention and baseline characteristics

Time frame: 20 years

Secondary Outcomes

Disease-free survival

Analyzed only for patients in complete response, as time from achievement of the complete response to relapse or death due to disease or acute toxicity of treatment, stratified according to intervention and baseline characteristics

Time frame: 20 years

Progression-free survival

Analyzed for all patients, as time from diagnosis to progression of disease or death as a result of any cause, stratified according to intervention and baseline characteristics

Time frame: 20 years

Biological correlative studies

Association between clinical and biologic characteristics

Time frame: 20 years

Central Contacts

Alessandro Rambaldi, MD

CONTACT

+39.035.2673683 arambaldi@asst-pg23.it

Giuseppe Gritti, MD, PhD

CONTACT

+39.035.2673679 g.gritti@asst-pg23.it

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.